The RPCI Clinical Protocol and Data Management/Clinical Trials Office (CPDM) is a comprehensive resource that provides a full range of clinical research services for all RPCI investigators at all RPCI clinical sites and in the clinical sites of its affiliates. CPDM is directed by Joyce Yasko, PhD, with Assistant Director Laurie Musial RN, MS and overseen by Alex Adjei, MD, PhD, Associate Director for Clinical Research. CPDM provides resources and oversight for the development, review, implementation, and conduct of clinical research studies and tracks regulatory documents. In collaboration with the study principal investigator, CPDM submits studies and amendments to the Scientific Review Committee (SRC) and Institutional Review Board (IRB) and submits continuing reviews to the IRB. CPDM also provides administrative support for the Clinical Research Prioritization and Feasibility Committee (CRPC), Scientific Review Committee (SRC), Response Review Committee (RRC), Phase I Committee and the Data and Safety Monitoring Board (DSMB). CPDM prepares, negotiates and manages study budgets and contracts; provides study sponsors and regulatory agencies with all required study documents;coordinates the conduct of all RPCI clinical studies and ensures that complete and accurate study data are collected and entered into a centralized electronic research database (eClinical). CPDM also ensures that all adverse events are reported promptly and accurately. In CY 2012, CPDM managed 213 active intervention studies with an accrual of 870 participants (1235 consented accrual) and 256 non-intervention studies with an accrual of 591,727 participants. The RPCI Data &Safety Monitoring Board (DSMB) coordinates and provides oversight for data and safety monitoring for all treatment intervention studies consistent with the NIH Policy for Data and Safety Monitoring dated June 10, 1998. The revised Roswell Park Cancer Institute Data &Safety Monitoring Plan (DSMP) was approved by the National Cancer Institute on April 4, 2011

Public Health Relevance

The Clinical Protocol and Data Management (CPDM) office provides the necessary infrastructure to conduct clinical investigations and to translate the basic research at Roswell Park Cancer Institute into cancer-relevant clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8738372
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$231,955
Indirect Cost
$91,748
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Li, Qiuhui; Deng, Qu; Chao, Hsueh-Ping et al. (2018) Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun 9:3600
Rossetti, Stefano; Wierzbicki, Andrzej J; Sacchi, Nicoletta (2018) Undermining ribosomal RNA transcription in both the nucleolus and mitochondrion: an offbeat approach to target MYC-driven cancer. Oncotarget 9:5016-5031
Mett, V; Komarova, E A; Greene, K et al. (2018) Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. Oncogene 37:439-449
Long, Mark D; Singh, Prashant K; Russell, James R et al. (2018) The miR-96 and RAR? signaling axis governs androgen signaling and prostate cancer progression. Oncogene :
Kawaguchi, Tstutomu; Yan, Li; Qi, Qianya et al. (2018) Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer. Ann Surg Oncol 25:4037-4046
Vexler, Albert; Yu, Jihnhee; Zhao, Yang et al. (2018) Expected p-values in light of an ROC curve analysis applied to optimal multiple testing procedures. Stat Methods Med Res 27:3560-3576
Mussell, Ashley L; Denson, Kayla E; Shen, He et al. (2018) Loss of KIBRA function activates EGFR signaling by inducing AREG. Oncotarget 9:29975-29984
Hirose, Yuki; Nagahashi, Masayuki; Katsuta, Eriko et al. (2018) Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis. Sci Rep 8:10814
Kesterson, Joshua P; Szender, J Brian; Schaefer, Eric et al. (2018) Evaluation of Association Between Gynecologic Oncology Fellowship Length and a Career in Academic Medicine. J Cancer Educ 33:141-146

Showing the most recent 10 out of 1555 publications